The right outsourcing partner should open up access to expertise and technical capabilities in a broad range of dosage forms to ensure commercial success.August 1, 2020Volume 2020 Supplement, Issue 3Page Number: s6-s9By Felicity Thomas, Pharmaceutical Technology As the need for innovation in drug development is increasing, so too is the requirement for companies to partner with a contract...
Multiple-unit pellet system (MUPS) can offer a solution to complex dose control Oral solid dose (OSD) delivery remains the most popular route for administering drugs. Market forces are prompting pharmaceutical companies to pursue a broad array of OSD development strategies to make their active pharmaceutical ingredients (APIs) and formulations therapeutically effective and patient friendly. One...
Sitting Down with Bobby Sheng, Chairman and CEO of Bora Pharmaceuticals, TaiwanThe Medicine Maker's Interview with Bobby Sheng by James Strachan | 07/22/2020 | Link to the Interview Did you always want to work in pharma? My upbringing was a little unusual in that my father owned a pharmaceutical company in Taiwan. Every summer, I worked in the warehouse or the office, and I always felt that the...
The Podcast, "Molecule to Market" features Bobby ShengListen to podcast In this episode of the podcast - "Molecule to Market," you’ll go inside the outsourcing space of the global drug development sector with Bobby Sheng, CEO and Chairman of Bora Pharmaceuticals. A California native and an experienced leader in the pharmaceutical industry, Bobby is skilled in international business, management,...